CSIMarket
 
Xencor Inc  (XNCR)
Other Ticker:  
 
 
Price: $22.2500 $-0.84 -3.638%
Day's High: $23.8 Week Perf: -2.41 %
Day's Low: $ 22.07 30 Day Perf: 4.46 %
Volume (M): 525 52 Wk High: $ 30.21
Volume (M$): $ 11,683 52 Wk Avg: $22.87
Open: $22.99 52 Wk Low: $16.49



 Market Capitalization (Millions $) 1,349
 Shares Outstanding (Millions) 61
 Employees 201
 Revenues (TTM) (Millions $) 168
 Net Income (TTM) (Millions $) -126
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 21

Xencor Inc
Xencor Inc is a biopharmaceutical company that uses its proprietary XmAb technology platform to develop and commercialize novel antibody therapeutics. The company's mission is to improve patient outcomes and quality of life by developing innovative and differentiated therapeutics.

Xencor's XmAb technology platform is a versatile antibody engineering technology that enhances the efficacy and safety of antibodies. It can be used to improve the half-life of antibodies, increase their potency, and reduce their immunogenicity. The XmAb technology platform has been applied to the development of several antibody candidates in various therapeutic areas including oncology, autoimmune diseases, and allergic diseases.

One of the key strengths of Xencor is its collaboration strategy. The company has partnered with several pharmaceutical and biotechnology companies including Novartis, Alexion Pharmaceuticals, and MorphoSys to develop and commercialize XmAb-based therapeutics. Xencor has also entered into research collaborations with academic institutions and government agencies.

Xencor has a diverse pipeline with several candidates in different stages of clinical development. The company's lead candidate, XmAb5871, is a first-in-class monoclonal antibody that targets the FceRIIb receptor on B cells. It is being developed for the treatment of autoimmune diseases including systemic lupus erythematosus and IgG4-related disease. XmAb7195 is another candidate being developed in collaboration with Novartis for the treatment of acute myeloid leukemia and other hematologic malignancies.

In addition to its pipeline of candidates, Xencor also has a robust technology portfolio. The company has developed several proprietary technologies including Xtende Fc technology, which extends the half-life of antibodies, and bispecific Fc technology that enables the creation of bispecific antibodies with improved therapeutic properties.

Overall, Xencor is a leading biopharmaceutical company with a promising pipeline of candidates and innovative technology platform. The company's collaborations, proprietary technologies, and diverse pipeline positions it to continue to deliver value to patients and shareholders in the years to come.


   Company Address: 465 North Halstead Street Pasadena 91107 CA
   Company Phone Number: 305-5900   Stock Exchange / Ticker: NASDAQ XNCR
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Xencor Inc

Xencor Inc Plunges into Losses Despite Revenue Surge

Xencor Inc Reports Strong Revenue Growth Despite Losses
Xencor Inc, a clinical-stage biopharmaceutical company specializing in engineered antibodies for the treatment of cancer and other serious diseases, recently announced very strong revenue growth of 106.798% year on year, reaching $44.69 million in the financial three months closing on December 31, 2023. However, losses have also increased, reaching $-0.30.
Despite the increase in losses, there has been significant improvement in earnings per share (EPS) compared to the previous reporting season. EPS improved from $-0.40 per share to $-0.30 per share. Additionally, although revenue fell by -24.466% from $59.16 million, the latest revenue results are still positive.

Management Changes

Xencor Advances Corporate Strategy with Addition of Dane Leone as Senior Vice President

Published Tue, Jan 2 2024 1:01 PM UTC



Xencor, a leading clinical-stage biopharmaceutical company specializing in engineered antibodies and cytokines, announced in a recent press release that Dane Leone, a seasoned financial expert, has joined the firm as the senior vice president of corporate strategy. This strategic appointment will bolster Xencor's ongoing efforts in enhancing its platform technolog...

Xencor Inc

Xencor Inc Reports Exponential Revenue Growth in Fiscal Third Quarter of 2023

Xencor Inc (NASDAQ: XNCR), a clinical-stage biopharmaceutical company, recently announced impressive revenue growth of 116.726% year on year in the fiscal third quarter of 2023, reaching $59.16 million. However, the company reported a loss of $-0.40 per share during the same period.
In comparison to its peers in the Major Pharmaceutical Preparations industry, Xencor Inc showed significant growth. While the average top-line advance for the industry's other two businesses was only 2.06% from the third quarter of 2022, Xencor Inc's growth far outpaced that at 116.726%.

Product Service News

Xencor: Spearheading Innovative Treatments and Surpassing Revenue Expectations in the Pursuit of a Healthier Future

Published Fri, Nov 3 2023 4:01 PM UTC



Xencor, Inc., a renowned clinical-stage biopharmaceutical company focused on developing engineered antibodies and cytokines for cancer and autoimmune diseases, recently presented exciting preclinical data from its multiple XmAb research programs at the prestigious 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The company's dedication to mol...

Xencor Inc

Xencor Inc Transforms Deficit into Opportunity with an Unprecedented 50.863% Revenue Surge in Q2 2023

Energetic Revenue Growth Fuels Positive Outlook for Xencor Inc, while Stock Performance Shows Potential
Investors in Xencor Inc, a leading biotechnology company, have reason to be optimistic as the company experienced impressive revenue growth in its most recent fiscal period. The company's revenue increased by a remarkable 50.863% to $45.52 million, resulting in a reduction of losses per share from $-0.57 in the corresponding reporting period a year ago to $-0.37 in the current period.
Xencor Inc's business performance outpaced that of its major peers in the Major Pharmaceutical Preparations industry during the second quarter of 2023. While the two other corporations in the industry saw a growth rate of 5.28% from the previous year, Xencor Inc's growth was substantially higher. This demonstrates the company's ability to excel in a competitive market.






 

Xencor Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Xencor Inc does not provide revenue guidance.

Earnings Outlook
Xencor Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com